We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum, Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00.
Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with moxifloxacin shortened the duration of therapy. In summary, while the regimens with moxifloxacin caused a [...]
The Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease.
The Kick TB Campaign is a unique project that uses the World’s most popular sport to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of the 2014 World Cup.
The European Commission has approved delaminid (Deltyba) for use in patients suffering from MDR-TB.
TB Alliance announces STAND, a Phase 3 Clinical Trial aimed at shortening the duration of treatment for drug-sensitive and MDR-TB.
TB Alliance, an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB.
The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.
A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.
You are invited to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2013 in Paris, France on Oct. 29th. Agenda included.